Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors.

Janes H, Brown MD, Glidden DV, Mayer KH, Buchbinder SP, McMahan VM, Schechter M, Guanira J, Casapia M.

PLoS One. 2019 Sep 19;14(9):e0222183. doi: 10.1371/journal.pone.0222183. eCollection 2019.

2.

PrEP Persistence is a Critical Issue in PrEP Implementation.

Spinelli MA, Buchbinder SP.

Clin Infect Dis. 2019 Sep 12. pii: ciz896. doi: 10.1093/cid/ciz896. [Epub ahead of print] No abstract available.

PMID:
31509603
3.

Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.

J Virol. 2019 Oct 15;93(21). pii: e02041-18. doi: 10.1128/JVI.02041-18. Print 2019 Nov 1.

PMID:
31434737
4.

Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city.

Spinelli MA, Hessol NA, Schwarcz S, Hsu L, Parisi MK, Pipkin S, Scheer S, Havlir D, Buchbinder SP.

AIDS. 2019 Sep 1;33(11):1789-1794. doi: 10.1097/QAD.0000000000002287.

PMID:
31259765
5.

Ending AIDS in the United States-If Not Now, When?

Havlir DV, Buchbinder SP.

JAMA Intern Med. 2019 Jun 11. doi: 10.1001/jamainternmed.2019.1577. [Epub ahead of print] No abstract available.

PMID:
31184750
6.

STIs: an unintended consequence of improved sexual health?

Scott HM, Buchbinder SP.

Lancet HIV. 2019 Jul;6(7):e415-e416. doi: 10.1016/S2352-3018(19)30140-7. Epub 2019 Jun 6. No abstract available.

PMID:
31178285
7.

CROI 2019: advances in HIV prevention and plans to end the epidemic.

Buchbinder SP, Liu AY.

Top Antivir Med. 2019 Apr;27(1):8-25. Review.

8.

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM.

AIDS Res Hum Retroviruses. 2019 Sep;35(9):788-793. doi: 10.1089/AID.2018.0297. Epub 2019 Jun 19.

PMID:
31119944
9.

The aspirational necessity of HIV prevention.

Corey L, Gray GE, Buchbinder SP.

J Int AIDS Soc. 2019 May;22(5):e25289. doi: 10.1002/jia2.25289. No abstract available.

10.

Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.

Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):158-162. doi: 10.1097/QAI.0000000000002005.

PMID:
31095005
11.

Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Gonzalez R, Morehead-Gee A, Gandhi M, Buchbinder SP.

Open Forum Infect Dis. 2019 Feb 26;6(4):ofz101. doi: 10.1093/ofid/ofz101. eCollection 2019 Apr.

12.

High Interest in Doxycycline for Sexually Transmitted Infection Postexposure Prophylaxis in a Multicity Survey of Men Who Have Sex With Men Using a Social Networking Application.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Coleman K, Buchbinder SP.

Sex Transm Dis. 2019 Apr;46(4):e32-e34. doi: 10.1097/OLQ.0000000000000942.

PMID:
30870327
13.

Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.

Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M.

AIDS. 2019 Apr 1;33(5):867-872. doi: 10.1097/QAD.0000000000002135.

PMID:
30649051
14.

Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Morehead-Gee A, Gonzalez R, Gandhi M, Buchbinder SP.

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):347-351. doi: 10.1097/QAI.0000000000001828.

15.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA.

JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.

16.

Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Morehead-Gee A, Gonzalez R, Buchbinder SP.

Open Forum Infect Dis. 2018 May 4;5(6):ofy099. doi: 10.1093/ofid/ofy099. eCollection 2018 Jun.

17.

CROI 2018: Epidemic Trends and Advances in HIV Prevention.

Buchbinder SP, Liu AY.

Top Antivir Med. 2018 May;26(1):1-16.

18.

Maximizing the Benefits of HIV Preexposure Prophylaxis.

Buchbinder SP.

Top Antivir Med. 2018 Apr;25(4):138-142.

19.

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis.

Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY.

AIDS Patient Care STDS. 2018 Mar;32(3):104-111. doi: 10.1089/apc.2017.0255.

20.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

21.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

22.

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

23.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.

PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.

24.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

25.

CROI 2017: HIV Epidemic Trends and Advances in Prevention.

Liu AY, Buchbinder SP.

Top Antivir Med. 2017 May/Jun;25(2):35-50.

26.

International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status.

Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM.

Sex Transm Dis. 2017 May;44(5):306-309. doi: 10.1097/OLQ.0000000000000601.

27.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

28.

CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention.

Buchbinder SP, Liu AY.

Top Antivir Med. 2016 May-Jun;24(1):10-28. Review.

29.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

30.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

31.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

32.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.

Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

33.

CROI 2015: Advances in HIV Testing and Prevention Strategies.

Buchbinder SP, Liu AY.

Top Antivir Med. 2015 Mar-Apr;23(1):8-27.

34.

Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.

Liu AY, Hessol NA, Vittinghoff E, Amico KR, Kroboth E, Fuchs J, Irvin R, Sineath RC, Sanchez T, Sullivan PS, Buchbinder SP.

AIDS Patient Care STDS. 2014 Dec;28(12):622-7. doi: 10.1089/apc.2014.0195.

35.

Can male circumcision have an impact on the HIV epidemic in men who have sex with men?

Goodreau SM, Carnegie NB, Vittinghoff E, Lama JR, Fuchs JD, Sanchez J, Buchbinder SP.

PLoS One. 2014 Jul 30;9(7):e102960. doi: 10.1371/journal.pone.0102960. eCollection 2014.

36.

A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.

Cousins MM, Konikoff J, Sabin D, Khaki L, Longosz AF, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Kobin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.

PLoS One. 2014 Jun 26;9(6):e101043. doi: 10.1371/journal.pone.0101043. eCollection 2014.

37.

CROI 2014: New tools to track the epidemic and prevent HIV infections.

Buchbinder SP, Liu AY.

Top Antivir Med. 2014 May;22(2):579-93. Review.

38.

Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial.

Coombs A, McFarland W, Ick T, Fuqua V, Buchbinder SP, Fuchs JD.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):e94-7. doi: 10.1097/QAI.0000000000000197. No abstract available.

39.

Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.

Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, Macalino GE.

Clin Infect Dis. 2014 Jun;58(12):1786-7. doi: 10.1093/cid/ciu229. Epub 2014 Apr 12. No abstract available.

40.

Immunology. Immune activation with HIV vaccines.

Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP.

Science. 2014 Apr 4;344(6179):49-51. doi: 10.1126/science.1250672. No abstract available.

41.

HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.

Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM.

Lancet Infect Dis. 2014 Jun;14(6):468-75. doi: 10.1016/S1473-3099(14)70025-8. Epub 2014 Mar 7.

42.

LILRB2 interaction with HLA class I correlates with control of HIV-1 infection.

Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, Bream JH, Duggal P, Hussain S, Martinson J, Weintrob A, Kirk GD, Fellay J, Buchbinder SP, Goedert JJ, Deeks SG, Pereyra F, Trowsdale J, Lichterfeld M, Telenti A, Walker BD, Allen RL, Carrington M, Yu XG.

PLoS Genet. 2014 Mar 6;10(3):e1004196. doi: 10.1371/journal.pgen.1004196. eCollection 2014 Mar.

43.

Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.

Marcus JL, Buisker T, Horvath T, Amico KR, Fuchs JD, Buchbinder SP, Grant RM, Liu AY.

HIV Med. 2014 Aug;15(7):385-95. doi: 10.1111/hiv.12132. Epub 2014 Feb 24. Review.

44.

Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).

Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M.

PLoS One. 2014 Jan 8;9(1):e83736. doi: 10.1371/journal.pone.0083736. eCollection 2014.

45.

Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States.

Scott HM, Vittinghoff E, Irvin R, Sachdev D, Liu A, Gurwith M, Buchbinder SP.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):115-21. doi: 10.1097/QAI.0b013e3182a98bae.

46.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

47.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, Laeyendecker O.

PLoS One. 2013 Dec 27;8(12):e82772. doi: 10.1371/journal.pone.0082772. eCollection 2013.

48.

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.

PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997. eCollection 2013.

49.

HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm.

Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.

J Clin Microbiol. 2014 Jan;52(1):115-21. doi: 10.1128/JCM.02040-13. Epub 2013 Oct 23.

50.

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.

Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker LG.

Int J STD AIDS. 2014 Apr;25(5):332-40. doi: 10.1177/0956462413506892. Epub 2013 Oct 8.

Supplemental Content

Loading ...
Support Center